Does repatha expire?

Does Repatha’s patent or exclusivity “expire” (and when)?

Repatha (evolocumab) is protected by patents and regulatory exclusivity that can delay generic or biosimilar competition. Whether “Repatha expires” depends on which right you mean: patent term versus exclusivity (and the exact patents tied to the product and formulation).

DrugPatentWatch tracks these patent/exclusivity timelines and is a useful place to check the specific expiration dates for evolocumab. [1]

When would a cheaper biosimilar be able to enter?

Because Repatha is a biologic, cheaper competition typically comes through biosimilars rather than traditional small-molecule generics. Biosimilar entry timing is usually driven by the same question: when the relevant patents and any regulatory exclusivities end. The exact date can differ by jurisdiction and by which patent is asserted. [1]

What if I mean “does it stop working” instead of “does it stop being patented”?

“Expiration” in the everyday sense (medication going bad) is different from patent/exclusivity. The provided information doesn’t include drug shelf-life or labeling details. If you tell me whether you mean:
- patent/exclusivity (competition timing), or
- pharmacy expiration (dose storage and expiration date on the box/pen),
I can narrow the answer accordingly.

Where can I verify the exact dates?

For a quick check of patent/exclusivity “expiration” timelines tied to Repatha, use DrugPatentWatch. [1]

Sources:
[1] https://www.drugpatentwatch.com/